KORU Medical Systems (NASDAQ:KRMD) Announces Earnings Results, Meets Estimates

Key Points

• Q1 results: revenue of $11.8M (+22% YoY) and EPS of ($0.02) met estimates; adjusted EBITDA was essentially break‑even, net loss improved 33% to $0.8M, and cash usage was minimal at $0.1M leaving about $8.8M on the balance sheet.
• Management reiterated full‑year 2026 guidance of $47.5M–$50M revenue (15%–22% growth), 61%–63% gross margin and expects positive adjusted EBITDA and cash flow, while retaining access to a $10M debt facility despite Q1 margin compression.
• Commercial and pipeline momentum: international core sales grew ~35% driven by EU prefilled‑syringe conversions and distributor pump orders (supported by Freedom60 MDR clearance), and the non‑IG pipeline now includes eight active opportunities with two partners in phase III and a 510(k) submitted for deferoxamine.

KORU Medical Systems (NASDAQ:KRMD - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.02) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.02), Zacks reports. The firm had revenue of $11.76 million for the quarter, compared to the consensus estimate of $11.28 million. KORU Medical Systems had a negative return on equity of 15.90% and a negative net margin of 6.41%.

Here are the key takeaways from KORU Medical Systems' conference call:

• Q1 results beat expectations with $11.8M revenue (+22% YoY), adjusted EBITDA essentially break‑even (-$10k) and net loss improving 33% to $0.8M, while cash usage was minimal at $0.1M leaving $8.8M on the balance sheet.
• Management reiterated full‑year 2026 guidance of $47.5M–$50M revenue (15%–22% growth), 61%–63% gross margin, and positive adjusted EBITDA and cash flow, and retains access to a $10M debt facility.
• International expansion showed strong traction (international core +35%) driven by EU prefilled‑syringe conversions and distributor pump orders, supported by Freedom60 MDR clearance for prefilled syringe compatibility.
• The non‑IG pipeline advanced—now eight active non‑IG opportunities (>6M potential annual infusions), two pharma partners moved into phase III (including Apellis EMPAVELI in DGF), and a 510(k) was submitted for deferoxamine, while vancomycin was deprioritized.
• Q1 gross margin compressed to 61.5% (down 130 bps) due to production timing and tariff charges, although management says adjusted margins and cost initiatives keep full‑year margin guidance intact.

KORU Medical Systems Stock Performance

Shares of NASDAQ KRMD traded down $0.07 during midday trading on Wednesday, reaching $4.01. 151,549 shares of the stock were exchanged, compared to its average volume of 138,622. The stock has a market capitalization of $186.91 million, a P/E ratio of -66.83 and a beta of 0.43. The company has a 50 day simple moving average of $4.34 and a 200 day simple moving average of $4.85. KORU Medical Systems has a twelve month low of $2.63 and a twelve month high of $6.61.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. B. Riley Financial raised their price target on KORU Medical Systems from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Friday, March 13th. Wall Street Zen lowered KORU Medical Systems from a "strong-buy" rating to a "buy" rating in a research report on Sunday, April 26th. Weiss Ratings restated a "sell (d-)" rating on shares of KORU Medical Systems in a research report on Tuesday, April 21st. Canaccord Genuity Group reiterated a "buy" rating and issued a $6.00 price target on shares of KORU Medical Systems in a report on Friday, March 13th. Finally, Craig Hallum reissued a "buy" rating and issued a $7.00 price objective on shares of KORU Medical Systems in a research note on Tuesday, January 13th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $6.50.

Institutional Investors Weigh In On KORU Medical Systems

A number of hedge funds and other institutional investors have recently modified their holdings of the company. First Light Asset Management LLC increased its stake in KORU Medical Systems by 5.1% in the second quarter. First Light Asset Management LLC now owns 4,681,626 shares of the company's stock valued at $16,760,000 after purchasing an additional 226,700 shares during the period. Vanguard Group Inc. lifted its holdings in shares of KORU Medical Systems by 2.9% in the third quarter. Vanguard Group Inc. now owns 2,145,772 shares of the company's stock valued at $8,218,000 after purchasing an additional 60,109 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of KORU Medical Systems by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 1,022,860 shares of the company's stock valued at $5,944,000 after buying an additional 16,062 shares during the period. State Street Corp increased its position in KORU Medical Systems by 32.6% during the fourth quarter. State Street Corp now owns 602,645 shares of the company's stock worth $3,501,000 after purchasing an additional 148,166 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in KORU Medical Systems by 189.5% during the first quarter. Goldman Sachs Group Inc. now owns 242,781 shares of the company's stock worth $617,000 after purchasing an additional 158,914 shares during the last quarter. 58.60% of the stock is currently owned by institutional investors and hedge funds.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.